DK2681230T3 - Fremgangsmåde til isolering af osteopontin ved anvendelse af råmaterialer indeholdende caseinomakropeptid (cmp) - Google Patents
Fremgangsmåde til isolering af osteopontin ved anvendelse af råmaterialer indeholdende caseinomakropeptid (cmp) Download PDFInfo
- Publication number
- DK2681230T3 DK2681230T3 DK12706623.1T DK12706623T DK2681230T3 DK 2681230 T3 DK2681230 T3 DK 2681230T3 DK 12706623 T DK12706623 T DK 12706623T DK 2681230 T3 DK2681230 T3 DK 2681230T3
- Authority
- DK
- Denmark
- Prior art keywords
- milk
- raw material
- derived
- protein
- derived feed
- Prior art date
Links
- 102000004264 Osteopontin Human genes 0.000 title claims description 128
- 108010081689 Osteopontin Proteins 0.000 title claims description 128
- 238000000034 method Methods 0.000 title claims description 74
- 239000002994 raw material Substances 0.000 title claims description 42
- 235000013336 milk Nutrition 0.000 claims description 272
- 239000008267 milk Substances 0.000 claims description 272
- 210000004080 milk Anatomy 0.000 claims description 272
- 235000018102 proteins Nutrition 0.000 claims description 142
- 102000004169 proteins and genes Human genes 0.000 claims description 142
- 108090000623 proteins and genes Proteins 0.000 claims description 142
- 108010046377 Whey Proteins Proteins 0.000 claims description 72
- 102000007544 Whey Proteins Human genes 0.000 claims description 70
- 238000005349 anion exchange Methods 0.000 claims description 63
- 239000005862 Whey Substances 0.000 claims description 60
- 108010067454 caseinomacropeptide Proteins 0.000 claims description 40
- 235000009508 confectionery Nutrition 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 10
- 102000004407 Lactalbumin Human genes 0.000 claims description 9
- 108090000942 Lactalbumin Proteins 0.000 claims description 9
- 238000005571 anion exchange chromatography Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 9
- 102000008192 Lactoglobulins Human genes 0.000 claims description 8
- 108010060630 Lactoglobulins Proteins 0.000 claims description 8
- 238000011026 diafiltration Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 108010076119 Caseins Proteins 0.000 description 76
- 102000011632 Caseins Human genes 0.000 description 76
- 235000021247 β-casein Nutrition 0.000 description 29
- 239000002253 acid Substances 0.000 description 28
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 28
- 235000021240 caseins Nutrition 0.000 description 28
- 239000005018 casein Substances 0.000 description 23
- 239000012141 concentrate Substances 0.000 description 17
- 235000021249 α-casein Nutrition 0.000 description 17
- 239000000693 micelle Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000021119 whey protein Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940021722 caseins Drugs 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- -1 0.1 M NaCI Chemical compound 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010923 batch production Methods 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108010058314 rennet Proteins 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000021246 κ-casein Nutrition 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DFYULHRIYLAUJM-UHFFFAOYSA-N 3,4-diiodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C(I)=C1 DFYULHRIYLAUJM-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 235000020167 acidified milk Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000020202 standardised milk Nutrition 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Claims (16)
1. Fremgangsmåde til isolering af osteopontin fra et råmateriale, der er afledt af mælk, hvilken fremgangsmåde omfatter følgende trin: a) at tilvejebringe et råmateriale, som er afledt af mælk, og som omfatter osteopontin, hvilket råmateriale, der er afledt af mælk, har en pH i pH-området 3,6-6,5 ved 25 grader C og en specifik ledningsevne i området fra 0,4-1,0 S/m (4-10 mS/cm) ved 25 grader C, og hvor råmaterialet, der er afledt af mælk, endvidere omfatter - caseinomakropeptid i en mængde på mindst 1 vægt-% i forhold til den samlede proteinmængde af råmaterialet, som er afledt af mælk, b) at underkaste råmaterialet, der er afledt af mælk, for anionbytterkromatografi, hvilket indbefatter, at råmaterialet, der er afledt af mælk, bringes i kontakt med et anionbyttermedium, c) eventuelt at vaske anionbyttermediet og d) at udvinde proteinet, som er bundet til anionbyttermediet, hvorved der opnås en sammensætning, som omfatter isoleret osteopontin.
2. Fremgangsmåde ifølge krav 1, hvor råmaterialet, der er afledt af mælk, omfatter caseinomakropeptid (CMP) i en mængde i området fra 1-40 vægt-% i forhold til den samlede proteinmængde af råmaterialet, der er afledt af mælk.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor råmaterialet, der er afledt af mælk, omfatter CMP i en mængde på mindst 5 vægt-%.
4. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, endvidere omfatter et yderligere protein med et isoelektrisk punkt (pi) < 5,0.
5. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, omfatter et råmateriale, der er afledt af mælkeserum.
6. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, omfatter et råmateriale, der er afledt af sød valle.
7. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, har en pH i området fra 5,0-6,5.
8. Fremgangsmåde ifølge et af kravene 1-6, hvor råmaterialet, der er afledt af mælk, har en pH i pH-området 3,8-5,5 ved 25 grader C.
9. Fremgangsmåde ifølge et af de foregående krav, hvor trin a), hvor råmaterialet, der er afledt af mælk, tilvejebringes, indbefatter fjernelse af et præcipi-tat fra en forsuret væske, som skal danne råmaterialet, der er afledt af mælk.
10. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt mælk, omfatter alpha-lactalbumin i en mængde på mindst 1 vægt-% i forhold til den samlede proteinmængde af råmaterialet, der er afledt af mælk.
11. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, omfatter beta-lactoglobulin i en mængde på mindst 1 vægt-% i forhold til den samlede proteinmængde af råmaterialet, der er afledt af mælk.
12. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, omfatter en samlet proteinmængde i området fra 6-250 g/L af råmaterialet, der er afledt af mælk.
13. Fremgangsmåde ifølge et af de foregående krav, hvor råmaterialet, der er afledt af mælk, har en specifik ledningsevne i området fra 0,45-0,90 S/m (4,5-9,0 mS/cm) ved 25 grader C.
14. Fremgangsmåde ifølge et af kravene 1-12, hvor råmaterialet, der er afledt af mælk, har en specifik ledningsevne i området fra 0,4-0,7 S/m (4-7 mS/cm) ved 25 grader C.
15. Fremgangsmåde ifølge et af kravene 1-12, hvor råmaterialet, der er afledt af mælk, har en specifik ledningsevne i området fra 0,7-1,0 S/m (7-10 mS/cm) ved 25 grader C.
16. Fremgangsmåde ifølge et af de foregående krav, hvor den udvundne sammensætning endvidere underkastes et eller flere af fremgangsmådetrinnene udvalgt fra gruppen bestående af opkoncentrering, diafiltrering, fordampning af opløsningsmiddel, spraytørring og substitution af proteinbundne kationer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448775P | 2011-03-03 | 2011-03-03 | |
| EP11156826 | 2011-03-03 | ||
| PCT/EP2012/053748 WO2012117119A1 (en) | 2011-03-03 | 2012-03-05 | Method for isolating osteopontin using feeds containing cmp or casein species |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2681230T3 true DK2681230T3 (da) | 2016-03-21 |
Family
ID=44202290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12706623.1T DK2681230T3 (da) | 2011-03-03 | 2012-03-05 | Fremgangsmåde til isolering af osteopontin ved anvendelse af råmaterialer indeholdende caseinomakropeptid (cmp) |
| DK12707103.3T DK2681231T3 (da) | 2011-03-03 | 2012-03-05 | Fremgangsmåde til isolering af osteopontin ved anvendelse af koncentrerede råmaterialer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12707103.3T DK2681231T3 (da) | 2011-03-03 | 2012-03-05 | Fremgangsmåde til isolering af osteopontin ved anvendelse af koncentrerede råmaterialer |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9181325B2 (da) |
| EP (2) | EP2681230B1 (da) |
| JP (2) | JP5967665B2 (da) |
| KR (2) | KR101940830B1 (da) |
| CN (3) | CN105085649B (da) |
| AR (2) | AR088719A1 (da) |
| AU (2) | AU2012222312B2 (da) |
| BR (2) | BR112013022251B1 (da) |
| CA (2) | CA2828669C (da) |
| DK (2) | DK2681230T3 (da) |
| EA (2) | EA023615B1 (da) |
| ES (2) | ES2565380T3 (da) |
| HK (1) | HK1217961A1 (da) |
| MX (2) | MX2013010019A (da) |
| PL (2) | PL2681230T3 (da) |
| WO (2) | WO2012117120A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014519796A (ja) * | 2011-04-28 | 2014-08-14 | ゾール サーキュレイション インコーポレイテッド | バッテリー管理パラメータの拡散型配布 |
| NZ700295A (en) | 2012-03-28 | 2016-07-29 | Arla Foods Amba | Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles |
| EA034654B1 (ru) * | 2013-07-05 | 2020-03-03 | Арла Фудс Амба | Применение остеопонтина коровьего молока для повышения иммунорезистентности |
| US9661868B2 (en) * | 2013-07-16 | 2017-05-30 | Mead Johnson Nutrition Company | Expanded bed adsorption methods for isolation of basic milk proteins including lactoferrin |
| KR200482960Y1 (ko) | 2016-04-07 | 2017-03-21 | 오숙희 | 고주파 얼굴 축소 시술기 |
| IL264105B (en) * | 2016-07-06 | 2022-09-01 | Building Block Nutritionals Llc | Nutritional formulation |
| WO2018087532A1 (en) | 2016-11-08 | 2018-05-17 | Dentherapy Ltd | Compositions comprising fluoride and calcium and method for preparing them |
| WO2019122363A1 (en) * | 2017-12-22 | 2019-06-27 | Societe Des Produits Nestle S.A. | Extracts and their use |
| CN109613140B (zh) * | 2019-01-07 | 2021-10-08 | 雅士利国际集团有限公司 | 食品中酪蛋白磷酸肽的检测方法 |
| CA3182755A1 (en) | 2020-06-15 | 2021-12-23 | James W. McGrath Jr. | Nutritional formula |
| GB202010987D0 (en) | 2020-07-16 | 2020-09-02 | Dentherapy Ltd | Oral care compositions and methods |
| EP4326076A1 (en) * | 2021-04-19 | 2024-02-28 | Société des Produits Nestlé S.A. | Use of milk protein fractions as a source of osteopontin |
| CN113567573B (zh) * | 2021-07-09 | 2023-06-02 | 黑龙江飞鹤乳业有限公司 | 骨桥蛋白的分离方法和分析方法 |
| GB202110114D0 (en) | 2021-07-14 | 2021-08-25 | Dentherapy Ltd | Oral care compositions for use in treaatment |
| WO2024056840A1 (en) | 2022-09-16 | 2024-03-21 | Univerza V Ljubljani | Isolation of osteopontin and glycomacropeptide from whey |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU712430B2 (en) * | 1996-10-01 | 1999-11-04 | Massey University | Process for isolating high purity glycomacropeptide from dairy products |
| EP1043963A4 (en) | 1997-12-31 | 2001-02-07 | Depuy Orthopaedics Inc | OSTEOPONTIN-BASED COMPOSITION TO INCREASE BONE FORMATION |
| AU760048B2 (en) * | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| AU777698B2 (en) * | 1999-12-08 | 2004-10-28 | Massey University | Process for separation of whey proteins using a novel anion exchanger |
| WO2001049741A2 (en) | 2000-01-07 | 2001-07-12 | Arla Foods Amba | A process for isolation of osteopontin from milk |
| NZ507335A (en) | 2000-10-05 | 2004-10-29 | New Zealand Dairy Board | Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP |
-
2012
- 2012-03-05 KR KR1020137026175A patent/KR101940830B1/ko active IP Right Grant
- 2012-03-05 AU AU2012222312A patent/AU2012222312B2/en active Active
- 2012-03-05 EA EA201391204A patent/EA023615B1/ru not_active IP Right Cessation
- 2012-03-05 KR KR1020137026174A patent/KR101940829B1/ko active IP Right Grant
- 2012-03-05 BR BR112013022251-4A patent/BR112013022251B1/pt active IP Right Grant
- 2012-03-05 DK DK12706623.1T patent/DK2681230T3/da active
- 2012-03-05 ES ES12707103.3T patent/ES2565380T3/es active Active
- 2012-03-05 CN CN201510434329.3A patent/CN105085649B/zh active Active
- 2012-03-05 JP JP2013555900A patent/JP5967665B2/ja active Active
- 2012-03-05 EP EP12706623.1A patent/EP2681230B1/en active Active
- 2012-03-05 MX MX2013010019A patent/MX2013010019A/es active IP Right Grant
- 2012-03-05 AU AU2012222313A patent/AU2012222313B2/en active Active
- 2012-03-05 CN CN201280015375.4A patent/CN103476787B/zh active Active
- 2012-03-05 ES ES12706623.1T patent/ES2565379T3/es active Active
- 2012-03-05 WO PCT/EP2012/053749 patent/WO2012117120A1/en active Application Filing
- 2012-03-05 CN CN201280015495.4A patent/CN103492408B/zh active Active
- 2012-03-05 EP EP12707103.3A patent/EP2681231B1/en active Active
- 2012-03-05 CA CA2828669A patent/CA2828669C/en active Active
- 2012-03-05 CA CA2828746A patent/CA2828746C/en active Active
- 2012-03-05 PL PL12706623T patent/PL2681230T3/pl unknown
- 2012-03-05 WO PCT/EP2012/053748 patent/WO2012117119A1/en active Application Filing
- 2012-03-05 MX MX2013010017A patent/MX2013010017A/es active IP Right Grant
- 2012-03-05 US US14/002,614 patent/US9181325B2/en active Active
- 2012-03-05 EA EA201391203A patent/EA023367B1/ru not_active IP Right Cessation
- 2012-03-05 BR BR112013022252-2A patent/BR112013022252B1/pt active IP Right Grant
- 2012-03-05 DK DK12707103.3T patent/DK2681231T3/da active
- 2012-03-05 US US14/002,578 patent/US9181316B2/en active Active
- 2012-03-05 PL PL12707103T patent/PL2681231T3/pl unknown
- 2012-03-05 JP JP2013555901A patent/JP6012053B2/ja active Active
- 2012-03-06 AR ARP120100714A patent/AR088719A1/es active IP Right Grant
- 2012-03-06 AR ARP120100713A patent/AR085620A1/es active IP Right Grant
-
2016
- 2016-05-25 HK HK16105999.2A patent/HK1217961A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2681230T3 (da) | Fremgangsmåde til isolering af osteopontin ved anvendelse af råmaterialer indeholdende caseinomakropeptid (cmp) | |
| AU2003218623B2 (en) | A process of isolating lactoferrin | |
| Bazinet et al. | Separation of bioactive peptides by membrane processes: technologies and devices | |
| NZ614872B2 (en) | Method for isolating osteopontin using feeds containing cmp or casein species | |
| NZ614874B2 (en) | Method for isolating osteopontin using concentrated feeds |